Are GLP-1 Receptor Agonists Safe During Pregnancy?

Managing diabetes and weight in young women is essential. Recently, many patients have started using GLP-1 receptor agonists for these conditions. However, clinicians often worry about inadvertent exposure during early pregnancy. Therefore, a recent systematic review evaluated maternal pregnancy outcomes after peri-fertilization exposure.

Evaluating Maternal Risks of GLP-1 Receptor Agonists

First, the researchers analyzed data from eight studies involving over 186,000 pregnancies. Specifically, they measured the incidence of gestational diabetes, preterm birth, and preeclampsia. Consequently, they found no statistically significant increase in maternal pregnancy complications. For instance, preeclampsia and hypertensive disorders showed no increased risk.

Potential Benefits for Gestational Diabetes

Interestingly, some findings suggested a potential benefit. In fact, exploratory sensitivity analyses revealed a protective effect against gestational diabetes. This benefit could help patients who conceive while using these medications. Nevertheless, the primary studies showed high heterogeneity. Thus, doctors must interpret these results with caution.

Clinical Guidance for Indian Physicians

Currently, official guidelines recommend discontinuing these drugs before conception. Moreover, patients should stop therapy at least two months prior to planning pregnancy. If inadvertent exposure occurs, clinicians can reassure patients using this reassuring data. Furthermore, comprehensive prenatal monitoring remains essential for all exposed pregnancies.

Frequently Asked Questions

Q1: Are GLP-1 receptor agonists safe to continue during pregnancy?

Currently, clinical guidelines recommend discontinuing these medications at least two months before planned pregnancy, although early data show no major increased risks of maternal complications.

Q2: Do GLP-1 receptor agonists increase the risk of preeclampsia?

No, systematic reviews show no statistically significant increase in preeclampsia or hypertensive disorders of pregnancy with early gestational exposure.

References

1. Hattler E et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis. Obstet Gynecol. 2026 Jul 02. doi: 10.1097/AOG.0000000000006363. PMID: 42391628.
2. Brown JP et al. Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information. Ann Intern Med. 2026 Jun 09. doi: 10.7326/ANNALS-25-04820.
3. Kodali LSM et al. GLP-1 Receptor Agonist Exposure During Pregnancy: A Systematic Review and Meta-Analysis of Adverse Pregnancy Outcomes. JACC Adv. 2026 Apr 01. doi: 10.1016/j.jacadv.2026.100123.